KPV Dosage: What Studies Actually Used — Not a Recommendation

"KPV peptide dosage" gets searched about 1,500 times a month, and most of what answers it hands back a specific microgram amount with no traceable source. As our evidence review covers in full, KPV has never been tested in a completed human clinical trial of any kind — and, as this article reports below, even KPV's own foundational animal studies don't disclose a dose figure in their published abstracts. That's a real, checkable gap, not an editorial choice to withhold a number this review actually found.

What the animal studies disclose about dose — and what they don't

KPV's literature is overwhelmingly a mouse-and-rat colitis story, built by a small number of research groups over roughly two decades. Read specifically for dose, route, and schedule — rather than the efficacy outcomes our evidence review already covers — the record is thinner than the number of published studies would suggest:

• •The foundational 2008 colitis paper. The study that established KPV's anti-inflammatory effect in two mouse models of inflammatory bowel disease — DSS colitis and CD45RB(hi) transfer colitis — reports the treatment outcome ("KPV treatment... led to earlier recovery and significantly stronger regain of body weight") but does not state the dose amount, injection route, or dosing frequency anywhere in its published abstract¹. This review checked that abstract through two independent sources (NCBI's own eutils and Europe PMC's independently served copy) specifically to confirm the gap wasn't an artifact of one database truncating the text — it wasn't; neither source's abstract carries a dose figure.
• •The PepT1 mechanism paper, same year. A second 2008 study, which identified KPV's uptake mechanism via the PepT1 transporter, discloses the ROUTE for its mouse-colitis finding — "KPV was added to drinking water" — but not the concentration or total daily amount delivered that way². The same paper does report a real, specific number for a different part of its own experiment: in cultured human intestinal cells and T cells, "nanomolar concentrations of KPV inhibit the activation of NF-kappaB and MAP kinase inflammatory signaling pathways²." That's worth being precise about — a cell-culture concentration measured in a dish, not an animal dose or anything resembling a human dosing figure.
• •The newer drug-delivery studies. A 2017 mouse study (hyaluronic-acid nanoparticles) and a 2021 rat study (a rectal hydrogel) both engineered new delivery vehicles specifically to improve on plain KPV's own uptake and reported better outcomes than unencapsulated KPV — but both papers' own stated purpose was comparing delivery systems to each other, not establishing or reporting a baseline milligram dose for KPV itself.

Put plainly: across the located KPV animal literature, this review found real routes (oral, in drinking water) and real cell-culture concentrations (nanomolar, in a dish) — but not one published abstract stating an actual milligram or milligram-per-kilogram dose administered to a live animal. That's a narrower and more specific gap than "the animal data is thin" — it's that the specific number most "KPV dosage" searches are actually looking for isn't published in the literature this review could locate, full stop.

Why there's no KPV dosing chart on this page

The same reasoning our BPC-157 dosage article applies to a much larger animal literature applies here to a smaller one with an even more basic gap: there is no published dose figure to even attempt converting into a human schedule, for any of KPV's foundational animal studies. Layered on top of that is the fact our evidence review already establishes: zero completed human clinical trials of KPV exist under any of its names, so there is no human number to report as an alternative either. Numbers describing a "typical" KPV dose that circulate on vendor and forum sites are not traceable to any peer-reviewed study or public trial record this review located — repeating them would misrepresent an unvalidated figure as documented fact. Our KPV reconstitution calculator will do the vial-to-syringe arithmetic on a number you already have, without validating that number against anything published.

What this means if you're looking for a KPV dose

There is no validated KPV dosing schedule this site, or any other legitimate source, can responsibly hand you — not because the research is being summarized cautiously, but because the specific number doesn't appear in the published animal literature this review located, and no human trial exists to supply one instead. What is documented: KPV's oral-route colitis effect in mice was tested via drinking water, not injection; its cellular anti-inflammatory mechanism activates at nanomolar concentrations in cultured human cells; and newer delivery-engineering studies have improved on plain KPV's own performance without ever publishing a baseline dose for the un-encapsulated peptide. For the regulatory status behind why no approved KPV dose exists, and what genuinely hasn't been studied about KPV in humans, see our full evidence review. For the same non-recommendation approach applied to KPV's peptide-market neighbors, see our TB-500 dosage and side-effects review and our BPC-157 dosage article.